文献速递类风湿关节炎

多病共存对活动性类风湿关节炎新治疗启动及达标的影响:基于RISE注册的队列研究

Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-09-10

该回顾性队列研究利用RISE注册数据,纳入活动性RA患者(RAPID3队列15,626例,CDAI队列5,733例),评估多病共存(RxRisk指数)与新DMARD启动及达标(低疾病活动度或缓解)的关联。结果显示多病共存与新DMARD启动无关,但多病共存负担越高,达标几率越低(RAPID3队列每1单位RxRisk OR 0.95,95%CI 0.91-0.98;CDAI队列OR 0.94,95%CI 0.90-0.99)。

要点

  • 多病共存不阻碍活动性RA患者启动新DMARD。
  • 多病共存负担越高,RA治疗达标几率越低。
  • 最高多病共存负担者达标几率最低(RAPID3队列OR 0.54)。

核心结论

  • 多病共存与活动性RA患者新DMARD启动无关,但与较低的治疗达标几率相关。

研究设计与样本

  • 回顾性队列研究,使用RISE注册数据,纳入活动性RA成人患者。
  • 多病共存采用基于药物的RxRisk指数测量。
  • RAPID3队列15,626例,CDAI队列5,733例;其中1,558例(RAPID3)和834例(CDAI)启动新DMARD并有随访疾病活动度测量。

主要发现

  • 多病共存与新DMARD启动无关联。
  • 每增加1单位RxRisk,达标几率降低:RAPID3队列OR 0.95(95%CI 0.91, 0.98);CDAI队列OR 0.94(95%CI 0.90, 0.99)。
  • 最高多病共存负担者达标几率最低:RAPID3队列OR 0.54(95%CI 0.34, 0.85);CDAI队列OR 0.65(95%CI 0.37, 1.15)。

关键数值与推荐

  • 多病共存采用RxRisk药物基础指数测量,患者平均涉及6至7个RxRisk类别。
  • 达标定义为低疾病活动度或缓解。
  • 新DMARD启动为活动性RA中启动新的改善病情抗风湿药。

临床怎么用

  • 对多病共存负担高的活动性RA患者,应关注其达标几率可能较低。
  • 可能需要针对多病共存采取更整体的管理方法以优化RA疾病控制。

局限性

  • 回顾性队列设计。
  • 患者以中年、女性、白人为主。
  • 多病共存基于药物索引测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether multimorbidity is associated with treatment changes and achieving target disease activity thresholds in patients with active rheumatoid arthritis (RA). METHODS: We conducted a retrospective cohort study of adults with active RA within the Rheumatology Informatics System for Effectiveness (RISE) registry. Multimorbidity was measured using RxRisk, a medication-based index of chronic disease. We used multivariable logistic regression models to assess the associations of multimorbidity with the odds of initiating a new disease-modifying antirheumatic drug (DMARD) in active RA, and among those initiating a new DMARD, the odds of achieving low disease activity or remission. RESULTS: We identified 15,626 patients using the Routine Assessment of Patient Index Data 3 (RAPID3) cohort and 5,733 patients using the Clinical Disease Activity Index (CDAI) cohort. All patients had active RA, of which 1,558 (RAPID3) and 834 (CDAI) initiated a new DMARD and had follow-up disease activity measures. Patients were middle aged, female, and predominantly White, and on average received medications from 6 to 7 RxRisk categories. Multimorbidity was not associated with new DMARD initiation in active RA. However, a greater burden of multimorbidity was associated with lower odds of achieving treatment targets (per 1-unit RxRisk: RAPID3 cohort odds ratio [OR] 0.95 [95% confidence interval (95% CI) 0.91, 0.98]; CDAI cohort OR 0.94 [95% CI 0.90, 0.99]). Those with the highest burden of multimorbidity had the lowest odds of achieving target RA disease activity (RAPID3 cohort OR 0.54 [95% CI 0.34, 0.85]; CDAI cohort OR 0.65 [95% CI 0.37, 1.15]). CONCLUSION: These findings from a large, real-world registry illustrate the potential impact of multimorbidity on treatment response and indicate that a more holistic management approach targeting multimorbidity may be needed to optimize RA disease control in these patients.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. England BR, Yun H, Chen L, et al. Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry. Arthritis Care Res (Hoboken). 2022. PMID: 34338449. doi:10.1002/acr.24762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。